DK2084543T3 - Risikostratificering af akut koronarsyndrom ved hjælp af fragmenter/delpeptider af provasopressin, især copeptin eller neurophysin II - Google Patents
Risikostratificering af akut koronarsyndrom ved hjælp af fragmenter/delpeptider af provasopressin, især copeptin eller neurophysin II Download PDFInfo
- Publication number
- DK2084543T3 DK2084543T3 DK07846265.2T DK07846265T DK2084543T3 DK 2084543 T3 DK2084543 T3 DK 2084543T3 DK 07846265 T DK07846265 T DK 07846265T DK 2084543 T3 DK2084543 T3 DK 2084543T3
- Authority
- DK
- Denmark
- Prior art keywords
- coronary syndrome
- acute coronary
- diagnosis
- copeptin
- neurophysin
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2410/00—Assays, e.g. immunoassays or enzyme assays, involving peptides of less than 20 animo acids
- G01N2410/04—Oxytocins; Vasopressins; Related peptides
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/32—Cardiovascular disorders
- G01N2800/324—Coronary artery diseases, e.g. angina pectoris, myocardial infarction
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/50—Determining the risk of developing a disease
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Cell Biology (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- General Physics & Mathematics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Endocrinology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
Claims (19)
1. Fremgangsmåde til risikostratificering af akut koronarsyndrom, hvor der sker en bestemmelse af copeptin eller neurophysin II ved hjælp af en in-vitro diagnose.
2. Fremgangsmåde til risikostratificering af akut koronarsyndrom ifølge krav 1, til muliggørelse af identificering af patienter med forhøjet risiko og/eller en ufordelagtig prognose for akut koronarsyndrom, især myokardieinfarkt.
3. Fremgangsmåde til risikostratificering af akut koronarsyndrom ifølge krav 1 eller 2, hvor patienten er en symptomatisk eller asymptomatisk patient, især en ulykkespatient.
4. Fremgangsmåde til risikostratificering af akut koronarsyndrom ifølge et af kravene 1 til 3, til muliggørelse af en terapistyring af akut koronarsyndrom, især myokardieinfarkt, især indenfor intensivmedicin eller ulykkesmedicin.
5. Fremgangsmåde til risikostratificering af akut koronarsyndrom ifølge et af kravene 1 til 4, til muliggørelse af udførelse af kliniske beslutninger, især videreførende behandling og terapi ved hjælp af lægemidler, især indenfor intensivmedicin eller ulykkesmedicin.
6. Fremgangsmåde til in-vitro diagnosticering til muliggørelse af en tidlig diagnose indenfor 6 timer efter symptomernes optræden eller differentialdiagnose eller prognose af myokardieinfarkt, hvor der udføres en bestemmelse af copeptin eller neurophysin II af en patient, der skal undersøges.
7. Fremgangsmåde til risikostratificering af akut koronarsyndrom ifølge krav 1 eller fremgangsmåde til in-vitro diagnosticering til muliggørelse af en tidlig diagnose indenfor 6 timer efter symptomernes optræden eller differentialdiagnose eller prognose af myokardieinfarkt ifølge krav 6, hvor der udføres en bestemmelse af copeptin eller neurophysin II i kombination med natriuretiske proteiner, især ANP (eller ANF), proANP, NT-proANP, BNP, proBNP, NT- proBNP fra en patient, der skal undersøges.
8. Fremgangsmåde ifølge krav 7, kendetegnet ved, at diagnosen foretages med henblik på forebyggelse, prognosticering, differentialdiagnostisk tidlig konstatering og konstatering, bedømmelse af alvorsgraden og bedømmelse af terapiens forløb.
9. Fremgangsmåde ifølge et af de foregående krav, kendetegnet ved, at cut-off (tærskelværdien) til diagnosticering 6-20 pmol/L, især 6-10 pmol/L, eller cut-off (tærskelværdien) til prognosticering 10-30 pmol/L, især 10-20 pmol/L, af markøren copeptin eller neurophysin II er signifikant (specifik).
10. Fremgangsmåde ifølge et af de foregående krav, kendetegnet ved, at der endvidere udføres en bestemmelse af mindst en yderligere markør, der er valgt fra gruppen af inflammatoriske markører, kardiovaskulære markører, neurohormonale markører eller iskæmiske markører i en in-vitro diagnose.
11. Fremgangsmåde ifølge krav 10, kendetegnet ved, at den inflammatoriske markør er valgt blandt mindst en markør fra gruppen bestående af blandt C-reaktivt protein (CRP), cytokiner, såsom TNF-alpha, interleukiner, såsom IL-6, procalcitonin (1-116, 3-116) og adhæsionsmolekyler, såsom VCAM eller ICAM.
12. Fremgangsmåde ifølge krav 10, kendetegnet ved, at den kardiovaskulære markør er valgt blandt mindst en markør fra gruppen bestående af krea-tinkinase, myoglobin, myeloperoxidase, natriuretisk protein, især ANP (eller ANF), proANP, NT-proANP, BNP, proBNP, NT-proBNP eller i hvert tilfælde en delsekvens deraf, kardial troponin, CRP og kredsløbsregulerende (pro)hormon, såsom pro-gastri n-f rigø rende peptid (proGRP), pro-endothelin-1, pro-leptin, pro-neuropeptid-Y, pro-somatostatin, pro-neuropeptid-YY, proopiomelanocortin eller pro-adrenomedullin (proADM).
13. Fremgangsmåde ifølge krav 10, kendetegnet ved, at den iskæmiske markør er valgt blandt mindst markør fra gruppen bestående af troponin I og T, CK-MB.
14. Fremgangsmåde ifølge krav 10, kendetegnet ved, at den neurohormo-nale markør er mindst et natriuretisk protein, især ANP (eller ANF), proANP, NT-proANP, BNP, proBNP, NT-proBNP.
15. Fremgangsmåde ifølge et af de foregående krav, kendetegnet ved, at bestemmelserne udføres ved hjælp af en hurtig test, især i enkelt- eller multiparameterbestemmelser.
16. Fremgangsmåde ifølge et af de foregående krav, kendetegnet ved, at risikostratificeringen sker med henblik på prognosticering, differentialdiagno-stisk tidlig konstatering og konstatering, bedømmelse af alvorsgraden og bedømmelse af terapiens forløb ved akut koronarsyndrom.
17. Anvendelse af copeptin eller neurophysin II til risikostratificering af akut koronarsyndrom og/eller til in-vitro diagnosticering til muliggørelse af en tidlig diagnose indenfor 6 timer efter symptomernes optræden eller differentialdiagnose eller prognose af myokardieinfarkt.
18. Anvendelse af et kit til risikostratificering af akut koronarsyndrom eller tidlig diagnose indenfor 6 timer efter symptomernes optræden eller differentialdiagnose eller prognose af myokardieinfarkt indeholdende påvisningsreagenser til bestemmelse af copeptin eller neurophysin II og evt. yderligere markører ifølge et af kravene 10 til 14 og hjælpemidler.
19. Kit til diagnosticering af akut koronarsyndrom, myokardieinfarkt indeholdende påvisningsreagenser til bestemmelse af copeptin eller neurophysin II i kombination med natriuretiske proteiner, især ANP (eller ANF), proANP, NT-proANP, BNP, proBNP, NT-proBNP og evt. yderligere markører ifølge et af kravene 10 til 14 og hjælpemidler.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE200610050497 DE102006050497A1 (de) | 2006-10-26 | 2006-10-26 | Risikostratifizierung des akuten Koronarsyndroms mittels Fragmenten / Teilpeptiden des proVasopressins, insbesondere Copeptin oder Neurophysin II |
DE200610057409 DE102006057409A1 (de) | 2006-12-04 | 2006-12-04 | Risikostratifizierung des akuten Koronarsyndroms mittels Fragmenten / Teilpeptiden des proVasopressins, insbesondere Copeptin oder Neurophysin II |
PCT/DE2007/001928 WO2008049422A2 (de) | 2006-10-26 | 2007-10-26 | Risikostratifizierung des akuten koronarsyndroms mittels fragmenten / teilpeptiden des provasopressins, insbesondere copeptin oder neurophysin ii |
Publications (1)
Publication Number | Publication Date |
---|---|
DK2084543T3 true DK2084543T3 (da) | 2018-01-22 |
Family
ID=39276269
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK07846265.2T DK2084543T3 (da) | 2006-10-26 | 2007-10-26 | Risikostratificering af akut koronarsyndrom ved hjælp af fragmenter/delpeptider af provasopressin, især copeptin eller neurophysin II |
Country Status (9)
Country | Link |
---|---|
US (3) | US8501485B2 (da) |
EP (1) | EP2084543B1 (da) |
JP (2) | JP5320294B2 (da) |
DE (1) | DE112007003185A5 (da) |
DK (1) | DK2084543T3 (da) |
ES (1) | ES2652027T3 (da) |
HK (1) | HK1137808A1 (da) |
PL (1) | PL2084543T3 (da) |
WO (1) | WO2008049422A2 (da) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20140046407A1 (en) * | 2001-08-31 | 2014-02-13 | Bio Control Medical (B.C.M.) Ltd. | Nerve stimulation techniques |
EP1628136A1 (en) * | 2004-08-19 | 2006-02-22 | B.R.A.H.M.S. Aktiengesellschaft | Method of diagnosis of disease using copeptin |
JP2009534672A (ja) * | 2006-04-24 | 2009-09-24 | メディツィニシェ ウニベルジテート ウィーン | 心臓血管疾患を診断する方法 |
DE112007003185A5 (de) * | 2006-10-26 | 2009-10-01 | Brahms Aktiengesellschaft | Risikostratifizierung des akuten Koronarsyndroms mittels Fragmenten / Teilpeptiden des proVasopressins, insbesondere Copeptin oder Neurophysin II |
DE102006058266A1 (de) * | 2006-12-08 | 2008-06-12 | Brahms Aktiengesellschaft | Diagnose und Risikostratifizierung von Herzinsuffizienz mittels Neurophysin |
DE102007009751A1 (de) | 2007-02-28 | 2008-09-04 | B.R.A.H.M.S Aktiengesellschaft | Verfahren zur selektiven Bestimmung von Procalcitonin 1-116 für diagnostische Zwecke sowie Antikörper und Kits zur Durchführung eines solchen Verfahrens |
EP2356450B1 (en) | 2008-10-24 | 2019-02-06 | B.R.A.H.M.S GmbH | Prognosis and risk assessment in stroke patients by determining the level of marker peptides |
EP2356463B1 (en) * | 2008-10-31 | 2017-08-30 | B.R.A.H.M.S GmbH | Arginine vasopressin pro-hormone as predictive biomarker for diabetes |
WO2010128071A1 (en) * | 2009-05-05 | 2010-11-11 | Brahms Ag | Vasoactive hormone-based stratification of patients suffering from diseases related to endothelial function/dysfunction |
RU2618437C2 (ru) * | 2010-11-01 | 2017-05-03 | Б.Р.А.Х.М.С Гмбх | Оценка прогноза и риска пациентов с неспецифическими жалобами |
EP2533052A1 (en) * | 2011-06-07 | 2012-12-12 | B.R.A.H.M.S GmbH | Diagnostic use of proSomatostatin |
CN103917638A (zh) * | 2011-09-08 | 2014-07-09 | Nexusdx股份有限公司 | 多级分析物检定 |
WO2017136464A1 (en) | 2016-02-01 | 2017-08-10 | Prevencio, Inc. | Diagnostic and prognostic methods for cardiovascular diseases and events |
US11931207B2 (en) | 2018-12-11 | 2024-03-19 | Eko.Ai Pte. Ltd. | Artificial intelligence (AI) recognition of echocardiogram images to enhance a mobile ultrasound device |
US11446009B2 (en) | 2018-12-11 | 2022-09-20 | Eko.Ai Pte. Ltd. | Clinical workflow to diagnose heart disease based on cardiac biomarker measurements and AI recognition of 2D and doppler modality echocardiogram images |
US12001939B2 (en) | 2018-12-11 | 2024-06-04 | Eko.Ai Pte. Ltd. | Artificial intelligence (AI)-based guidance for an ultrasound device to improve capture of echo image views |
KR102318236B1 (ko) * | 2020-02-18 | 2021-10-26 | 한림대학교 산학협력단 | 혈중 코펩틴의 농도를 이용한 지연성 뇌허혈 진단 방법 |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9305142D0 (en) * | 1993-03-12 | 1993-04-28 | Medinnova Sf | Method |
EP1322957B1 (en) | 2001-05-04 | 2009-08-12 | Biosite Incorporated | Diagnostic markers of acute coronary syndromes and methods of use thereof |
MXPA03004105A (es) * | 2002-05-14 | 2004-10-15 | Hoffmann La Roche | Elaboracion de una prognosis en casos de enfermedad cardiaca usando una combinacion de marcadores. |
AU2003251966A1 (en) * | 2002-07-16 | 2004-02-02 | Woomera Therapeutics Inc | Compositions and uses thereof for identifying and targeting provasopressin-expressing cancer cells |
CA2485722A1 (en) * | 2003-10-22 | 2005-04-22 | Paul Lehmann | Soluble transferrin receptor |
EP1530047A1 (en) * | 2003-11-07 | 2005-05-11 | Roche Diagnostics GmbH | Proximal markers of arterial thrombosis and inflammation for risk stratification of coronary heart disease |
EP1628136A1 (en) * | 2004-08-19 | 2006-02-22 | B.R.A.H.M.S. Aktiengesellschaft | Method of diagnosis of disease using copeptin |
DE102004051847B4 (de) * | 2004-10-25 | 2008-09-18 | Dade Behring Marburg Gmbh | Verhältnis von PIGF und Flt-1 als prognostischer Parameter bei kardio-vaskulären Erkrankungen |
WO2007146229A2 (en) * | 2006-06-07 | 2007-12-21 | Tethys Bioscience, Inc. | Markers associated with arteriovascular events and methods of use thereof |
DE112007003185A5 (de) * | 2006-10-26 | 2009-10-01 | Brahms Aktiengesellschaft | Risikostratifizierung des akuten Koronarsyndroms mittels Fragmenten / Teilpeptiden des proVasopressins, insbesondere Copeptin oder Neurophysin II |
DE102006053442A1 (de) * | 2006-11-12 | 2008-05-15 | Brahms Aktiengesellschaft | Diagnose und Risikostratifizierung von Infektionen und chronischen Erkrankungen der Atemwege und Lunge mittels proVasopressin, insbesondere Copeptin oder Neurophysin II |
DE102006058266A1 (de) * | 2006-12-08 | 2008-06-12 | Brahms Aktiengesellschaft | Diagnose und Risikostratifizierung von Herzinsuffizienz mittels Neurophysin |
DE102007021443A1 (de) * | 2007-05-08 | 2008-11-13 | Brahms Aktiengesellschaft | Diagnose und Risikostratifizierung mittels NT-proET-1 |
EP2148203A1 (en) * | 2008-07-23 | 2010-01-27 | BRAHMS Aktiengesellschaft | Azurophilic granule proteases as markers in cardiological diseases |
EP2356450B1 (en) * | 2008-10-24 | 2019-02-06 | B.R.A.H.M.S GmbH | Prognosis and risk assessment in stroke patients by determining the level of marker peptides |
-
2007
- 2007-10-26 DE DE112007003185T patent/DE112007003185A5/de active Pending
- 2007-10-26 US US12/447,105 patent/US8501485B2/en active Active
- 2007-10-26 ES ES07846265.2T patent/ES2652027T3/es active Active
- 2007-10-26 WO PCT/DE2007/001928 patent/WO2008049422A2/de active Application Filing
- 2007-10-26 EP EP07846265.2A patent/EP2084543B1/de active Active
- 2007-10-26 DK DK07846265.2T patent/DK2084543T3/da active
- 2007-10-26 JP JP2009533659A patent/JP5320294B2/ja active Active
- 2007-10-26 PL PL07846265T patent/PL2084543T3/pl unknown
-
2010
- 2010-02-05 HK HK10101320.7A patent/HK1137808A1/xx unknown
-
2013
- 2013-04-03 JP JP2013077587A patent/JP2013178249A/ja active Pending
- 2013-07-25 US US13/951,084 patent/US9261517B2/en active Active
-
2016
- 2016-01-21 US US15/003,734 patent/US10254289B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
US9261517B2 (en) | 2016-02-16 |
WO2008049422A3 (de) | 2009-01-15 |
EP2084543B1 (de) | 2017-10-18 |
US20100028921A1 (en) | 2010-02-04 |
US10254289B2 (en) | 2019-04-09 |
EP2084543A2 (de) | 2009-08-05 |
HK1137808A1 (en) | 2010-08-06 |
PL2084543T3 (pl) | 2018-04-30 |
ES2652027T3 (es) | 2018-01-31 |
JP5320294B2 (ja) | 2013-10-23 |
US20130344513A1 (en) | 2013-12-26 |
US8501485B2 (en) | 2013-08-06 |
JP2010507786A (ja) | 2010-03-11 |
JP2013178249A (ja) | 2013-09-09 |
WO2008049422A2 (de) | 2008-05-02 |
DE112007003185A5 (de) | 2009-10-01 |
US20160131660A1 (en) | 2016-05-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK2084543T3 (da) | Risikostratificering af akut koronarsyndrom ved hjælp af fragmenter/delpeptider af provasopressin, især copeptin eller neurophysin II | |
JP5584695B2 (ja) | Adm及びbnpのレベルを決定することによる心疾患に罹患した患者の予後診断及びリスク評価 | |
DK2823314T3 (da) | Forudsigelse af resultat hos patienter med kronisk obstruktiv lungesygdom | |
US9261516B2 (en) | Diagnosis and risk stratification using NT-proET-1 | |
US8524463B2 (en) | Diagnosis and risk classification of acute coronary syndrome by means of CT-proET-1 in combination with NT-proBNP | |
CN107064525A (zh) | 用于测定患有心脏病或被怀疑发生或患有心脏病的患者中的氨基末端proANP的方法 | |
JP2010526305A5 (da) | ||
WO2017218911A1 (en) | BIOMARKERS TO PREDICT NEW ONSET HEART FAILURE WITH PRESERVED EJECTION FRACTION (HFpEF) | |
US7977072B2 (en) | Sandwich immunoassay for identifying partial proANP peptides | |
CA2646245A1 (en) | Means and methods for the differentiation of acute and chronic myocardial necrosis in symptomatic patients | |
JP6117805B2 (ja) | トロポニンおよびbnpに基づく発作のリスク患者および原因の診断 | |
WO2005071407A2 (en) | Methods of diagnosing acute coronary syndrome by measuring urotensin ii | |
JP2013210385A (ja) | ニューロフィジンを使用する心機能不全の診断および危険性の層化 | |
CN101600967B (zh) | 和肽素或后叶激素运载蛋白ii在制备急性冠状动脉综合征危险性分级试剂盒的用途 | |
US20180156822A1 (en) | Biomarker for cardiac disorders |